Discover
CRMD
CorMedix Inc.
8.47
1 x 8.42
1 x 17.50
bid
ask
+
0.62
7.90%
1 @ 05:39 AM
8.42 -0.05 (0.59%)
| Ytd | -27.17% | |
| 1y | -28.16% |
7.98
day range
8.53
6.13
52 week range
14.96
| Open | 7.99 | Prev Close | 7.85 | Low | 7.98 | High | 8.53 | Mkt Cap | 664.49M |
| Vol | 1.28M | Avg Vol | 1.32M | EPS | 2.17 | P/E | 3.90 | Forward P/E | 17.54 |
| Beta | 1.58 | Short Ratio | 5.12 | Inst. Own | 31.92% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 8.08 | 200-d Avg | 8.97 | 1yr Est | 16.25 |
CRMD News
benzinga.com
Nike, Shutterstock And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
US stock futures lower as Dow falls 100 points. Nike shares down 4% after Q4 results. Shutterstock,
zacks.com
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes
zacks.com
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reim
zacks.com
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds
benzinga.com
CorMedix Therapeutics Announces U.S. Court Of Appeals Affirmed Patent Infringement Judgement Ruling
The Federal Circuit's decision on Friday upheld the district court's findings that Nexus'